Axsome Therapeutics (NASDAQ: AXSM)
Axsome Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Axsome Therapeutics Company Info
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
News & Analysis
Investing in Biotech Stocks in 2025
Axsome Therapeutics Revenue Surges 66%
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses.
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Why Axsome Therapeutics Stock Is Soaring Today
Why Axsome Therapeutics Stock Is Skyrocketing Today
Axsome Delivers Strong Q3 Revenue Beat
Axsome Therapeutics surpassed revenue expectations in Q3, driven by strong sales from its key products.
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
1 Under-the-Radar Biotech Stock to Buy and Hold
It could be an industry giant in the making.
Valuation
Earnings Transcripts
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2024.
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024.
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2024.
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.